Richmond Pharmacology host ground breaking Early Phase Trials Integration seminar at the Royal Society of Medicine

Posted:
22
December 2005

Richmond Pharmacology host ground breaking Early Phase Trials Integration seminar at the Royal Society of MedicineThe Early Phase Trials Integration seminar held recently at the Royal Society of Medicine was seen as a huge success by all who attended.The seminar generated valuable discussions between guest speakers and the Pharmaceutical industry, and explored innovative new ways to maximize the efficiency and speed of Early Phase research.The seminar focused on the developments around EU Legislations which have re-defined the boundaries of Phase I and opened a new era of opportunity to expedite compounds through the Early Phases.World leading expert speakers from St George's University London, Mayday University Hospital & NHS trust and the ABPI outlined the new context within which clinical trials are conducted. Presentations on innovative new methodology were reviewed to identify how a CRO like Richmond Pharmacology can add value to pharmacology and patient studies.Pharmacology and patient studies can now be integrated or work independently of one another. Clinical & therapeutic innovations enable Early Phase research to deliver more dynamic and insightful studies, maximizing the probability of a compound reaching the later Phases.This new era of Early Phase research demands 3 foundations which were explored during the day:

  1. Commercial in- and out-patient facilities
  2. Acute NHS environment
  3. Therapeutic expertise

Delegate feedback has been positive. Everyone who attended benefited from the highly informative and educational day which was also accredited by the Faculty of Pharmaceutical Medicine (FPM).View presentations from the seminar

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more